How Analysts Feel About FRESENIUS SE &amp CO KGAA ORDINARY SHAR (OTCMKTS:FSNUF) After Decrease in Sellers?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUF) Logo

The stock of FRESENIUS SE &amp CO KGAA ORDINARY SHAR (OTCMKTS:FSNUF) registered a decrease of 9.64% in short interest. FSNUF’s total short interest was 1.40M shares in December as published by FINRA. Its down 9.64% from 1.55 million shares, reported previously. With 500 shares average volume, it will take short sellers 2803 days to cover their FSNUF’s short positions.

The stock decreased 17.54% or $9.59 during the last trading session, reaching $45.09. About 1,700 shares traded or 66.18% up from the average. Fresenius SE & Co. KGaA (OTCMKTS:FSNUF) has 0.00% since December 8, 2017 and is . It has underperformed by 15.62% the S&P500.

Fresenius SE & Co. KGaA, a health care group, provides services and products for dialysis, hospitals, and outpatient medical care worldwide. The company has market cap of $25.07 billion. The firm operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed divisions. It has a 10.67 P/E ratio. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

More notable recent Fresenius SE & Co. KGaA (OTCMKTS:FSNUF) news were published by: which released: “Fresenius: Proven Value Creation Amidst M&A Doubts – Seeking Alpha” on January 20, 2018, also with their article: “Fresenius SE – Is Last Year’s Underperformer A Good Investment For 2018? – Seeking Alpha” published on January 02, 2018, published: “Fresenius SE & Co. KGaA (FSNUF) Presents At BofAML 2017 Healthcare Conference – Seeking Alpha” on May 22, 2017. More interesting news about Fresenius SE & Co. KGaA (OTCMKTS:FSNUF) were released by: and their article: “Fresenius SE: A High Quality Healthcare Company Unfairly Punished By The Market – Seeking Alpha” published on February 12, 2018 as well as‘s news article titled: “Do You Know This European Dividend Aristocrat? – Seeking Alpha” with publication date: September 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.